What they now need to do IMO is move on with the extension trial ASAP. The reason I say this is I think it would be quickest way to extend patients past 12 weeks as they already have a willing population group that wouldn't have to be screened or searched out, cheapest option too I would think. If you look at the extremely well documented compassionate use patient #3 from the 2a report, you will notice a spike towards the 5 week mark, followed by a pull back in weeks 8 to 10, leading to another uptrend around week 12 that continues to rise to a higher peak and remain within that range for over 30 weeks. Today's results follow that exact same pattern to a "T" through 12 weeks. That's potentially huge as time goes forward with scores going higher and staying there while the placebo would be falling off even further making the results more and more significant the longer the trial goes. Today's data showed stat sig at the 5 week interval already.
Today's presentation showed that the completer population showed improvement over the placebo group at every single data point on both the ACDS and SIB scales. People can buy, sell, or trade this stock but that fact won't change. May take longer than we hope but I would think the open label extension would be the quickest path forward in ALZ. JMHO
News 
Market Data 
Discover 
